Ultragenyx Pharmaceutical Inc 2025年季度报告

OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.For the transion period fromto.Commission File No.001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware27-2546083(State or other jurisdicon of incorporaon or organizaon)(I.R.S. Employer Idenficaon No.) 60 Leveroni CourtNovato,California(Address of principal execuve offices) (415)483-8800(Registrant’s telephone number, including area code) Not Applicable(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securies registered pursuant to Secon 12(b) of the Act: Indicate by check mark whether the registrant (1) hasfiled all reports required to befiled by Secon 13 or 15(d) of the SecuriesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile suchreports), and (2) has been subject to suchfiling requirements for the past 90 days.YES☑NO☐ Indicate by check mark whether the registrant has submied electronically every Interacve Data File required to be submiedpursuant to Rule 405 of Regulaon S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit suchfiles).YES☑NO☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smallerreporng company, or an emerging growth company. See the definions of “large acceleratedfiler,” “acceleratedfiler,” “smallerreporng company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☑Non-acceleratedfiler☐ Acceleratedfiler☐Smaller reporng company☐Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transion period for complying with any new or revisedfinancial accounng standards provided pursuant to Secon 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☑ As of May 1, 2025, the registrant had94,542,035shares of common stock issued and outstanding. ULTRAGENYX PHARMACEUTICAL INC.FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2025INDEX CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS1 Item 2.Management’s Discussion and Analysis of Financial Condion and Results of Operaons21Item 3.Quantave and Qualitave Disclosures About Market Risk31Item 4.Controls and Procedures32 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or the Quarterly Report, contains forward-looking statements that involve risks anduncertaines. We make such forward-looking statements pursuant to the safe harbor provisions of the Private SecuriesLigaon Reform Act of 1995 and other federal securies laws. All statements other than statements of historical fact containedin this Quarterly Report are forward-looking statements. In some cases, you can idenfy forward-looking statements by wordssuch as "aim," “ancipate,” “believe,” “connue,” “could,” “esmate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potenal,”“predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negave of these words, or other comparable terminology.These forward-looking statements include, but are not limited to, statements about: •our commercializaon, markeng, and manufacturing capabilies and strategy;•our expectaons regarding theming of clinical study commencements and reporng results from same;•theming and likelihood of regulatory approvals for, or commercializaon of, our product candidates;•the ancipated indicaons for our product candidates, if approved;•the potenal market opportunies for commercializing our products and product candidates;•our expectaons regarding the potenal market size and the size of the paent populaons for our products and productcandidates, if approved for commercial use;•esmates of our expenses, revenue, capital requirements, and our needs for addionalfinancing;•our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical studies;•the implementaon of our business model and strategic plans for our business, products and product candidates and theintegraon and performance of any businesses we have acquired or may acquire;•the iniaon,ming, progress, and results of ongoing and future preclinical and clinical studies, and our research anddevelopment programs;•the scope of protecon we are able to establish and maintain for intellectual property rights covering our products andproduct candidates;•our ability to maintain and establish collaboraons or strategic relaonships or obtain addional funding;•our ability to maintain and establish relaonships with third pares, such as contract research organizaons, contractmanufacturing organizaons, suppliers, and distributors;•